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Abstract The aim of this study was to determine the preva-
lence rates of mucopolysaccharidoses in Poland and to com-
pare them with other European countries. A retrospective
epidemiological survey covering the period between 1970
and 2010 was implemented. Multiple ascertainment sources
were used to identify affected patients. The overall prevalence
of mucopolysaccharidoses in the Polish population was 1.81
per 100,000. Five different mucopolysaccharidoses were di-
agnosed in a total of 392 individuals. MPS III was the most
frequent mucopolysaccharidosis, with a birth prevalence of
0.86 per 100,000 live births. A prevalence of approximately
0.22 cases per 100,000 births was obtained for MPS I. For
MPS II, the prevalence was estimated as 0.45 cases per 100,000
births; for MPS IVA and B as 0.14 cases in 100,000 births; and
that for MPS VI as 0.03 cases per 100,000 births. 1. The
prevalence pattern of mucopolysaccharidosis in Poland is low-
er when compared to the prevalence reported for other
European countries, such as the Netherlands, Czech Republic,
or Germany, but similar to countries like Sweden and
Denmark. 2. Different frequencies of the various forms of
mucopolysaccharidosis were observed. 3. In the case of MPS
VI, the incidence values for Poland were the lowest of all the
studies previously published so far.
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Introduction
The mucopolysaccharidoses represent the largest group of
lysosomal storage disorders (LSDs) and are characterized by
progressivemultiorgan involvement, leading to severe disabil-
ity and premature death. Each type results from a deficiency of
a specific lysosomal enzyme that participates in the stepwise
degradation of glycosaminoglycans (GAGs) (Neufeld and
Muenzer 2001). Seven types of mucopolysaccharidosis disor-
ders, caused by deficiencies of ten different enzymes, are as
follows: MPS I (Hurler MIM 607014, Hurler–Scheie MIM
607015, Scheie MIM 607016), MPS II (Hunter syndrome
MIM 309900), MPS III A (MIM 252900), B (OMIM
252920), C (MIM 252930), or D (MIM 252940) (Sanfilippo
syndrome), MPS IV A (MIM 253000) or B (MIM 253010)
(Morquio syndrome), MPS VI (Maroteaux–Lamy syndrome,
MIM 253200), MPS VII (Sly disease, MIM 253220), and
MPS IX (MIM 601492) (Neufeld and Muenzer 2001). There is
a wide variety of clinical symptoms between and within each
type (Neufeld andMuenzer 2001).Mostmucopolysaccharidoses
are inherited in an autosomal recessive manner, with the excep-
tion of mucopolysaccharidosis type II, which shows X-linked
recessive inheritance.
A retrospective epidemiological survey study of the
mucopolysaccharidoses was implemented to estimate the
prevalence and incidence rates of the different types for the
period from 1970 until 2010 in Poland. There have been a
number of reports on the prevalence of particular disorders in
select populations. One of the first studies on the frequency of
mucopolysaccharidoses in the province of British Columbia
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(Canada) was carried out by Lowry and Renwick (1971).
These data were updated by Lowry et al. (1990) and later by
Applegarth et al. (2000). Further studies on the prevalence of
the various types of mucopolysaccharidoses in different pop-
ulations have shown considerable variation (Meikle et al.
1999; Poupetová et al. 2010; Poorthuis et al. 1999; Nelson
et al. 2003; Malm et al. 2008; Baehner et al. 2005). As the
development of therapies for this group of disorders proceeds
and the possibilities for neonatal screening are explored, it
becomes important to obtain accurate values for the preva-
lence of these disorders (Meikle et al. 1999). Treatment op-
tions for a number of mucopolysaccharidoses have rapidly
expanded and currently include enzyme replacement therapy
(ERT), substrate reduction, and hematopoietic stem cell trans-
plantation (Hollak and Wijburg 2014; Jakóbkiewicz-Banecka
et al. 2007). Current available treatment authorized in the EU
includes ERT for MPS I, II, IV, and VI (Hollak and Wijburg
2014). These data will be required in order to accurately assess
the cost of these disorders to public health care systems and
will be a key factor in the adoption of screening and treatment
programs (Meikle et al. 1999).
The aim of this study was to calculate the birth prevalence of
mucopolysaccharidoses in Poland and to compare the results
with reported epidemiologic data from other European countries.
Materials and methods
Patient enrolment and data collection
Data from individuals who had been diagnosed with
mucopolysaccharidosis at the Department of Genetics,
Institute of Psychiatry and Neurology in Warsaw between
1970 and 2010 have been analyzed. The Children’s
Memorial Health Institute is the only laboratory providing
diagnostic testing for mucopolysaccharidosis in Poland.
In order to obtain as complete an ascertainment as possible,
multiple sources were utilized:
1. Patient records from the Department of Metabolic Diseases,
The Children’s Memorial Health Institute, Warsaw, Poland.
2. Laboratory records from the Department of Genetics,
Institute of Psychiatry and Neurology, Warsaw, Poland.
3. Membership list of the Polish MPS Society (patient sup-
port group).
The patient list, presumed to be exhaustive, was then used
for the data collection.
Diagnosis of mucopolysaccharidosis
The initial diagnosis of mucopolysaccharidosis was based on
the demonstration of accumulated substrates (GAGs) in body
fluids using electrophoretic methods. The definite diagnosis
was made by demonstrating the deficiency of the relevant
enzyme and/or presence of pathogenic mutation.
Data analysis for prevalence rates
The live births numbers in Poland were obtained from the
GUS Central Statistical Office (XXXX). For the years 1970–
1990, in Poland, the live births numbers were available every
five years, while for the years 1990–2009, the live births
numbers were available annually. The missing live births
values were calculated using linear interpolation for the years
1983–1989 and using the least squares approach to estimate
the values for the year 2010 for Poland. The calculations of
incidence rates with specification of the confidence interval
were conducted using Windows Microsoft Excel 2007
software.
Confidence intervals (95 %) for the birth prevalences were
estimated from the Poisson distribution using Simple Interactive
Statistical Analysis (SISA) software (Uitenbroek 1997).
Carrier frequency was calculated using the Hardy–
Weinberg equation (Strachan and Read 2004).
Results
Prevalence rates in Poland
Live births registered at the Polish Bureau of Statistics in the
period from 1970 until 2010 totalled 21,686,890. In the past
four decades, a total of 392 patients have been diagnosed with
one of seven specific types of mucopolysaccharidoses in
Poland (Fig. 1). The number of diagnosed patients gradually
increased during the study period, from less than 10 cases per
year in the 1970s to 15–20 new cases diagnosed annually in
recent years. The combined birth prevalence for all
mucopolysaccharidoses is 1.81 per 100,000 live births. Data
on the prevalence rates are presented in Table 1.
To date, no individuals in the Polish population have been
diagnosed with MPS VII or MPS IX.
The incidence and prevalence rates for MPS VI in compar-
ison with other countries are presented in Table 2.
Discussion
The overall birth prevalence of mucopolysaccharidoses in the
Polish population (1.81 per 100,000 live births), which repre-
sents a Central European population, is lower when compared
to the prevalences reported for other European countries, such
as the Netherlands (4.5 per 100,000 live births), Czech
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Republic (3.72), and Germany (3.53). However, it is similar to
countries such as Denmark (1.77) and Sweden (1.75)
(Poupetová et al. 2010; Poorthuis et al. 1999; Malm et al.
2008; Baehner et al. 2005). The fact that there is only one
cente r involved in the enzymat ic d iagnos is of
mucopolysaccharidoses in Poland greatly facilitated the col-
lection of data for this study and, as a consequence, we have a
high level of confidence that few diagnoses were missed.
Obviously, it is possible that there are some individuals at
the less severe end of the clinical spectrum with some disor-
ders, particularly in the adult population, in whom
mucopolysaccharidosis was not diagnosed. Also, the unavail-
ability of some diagnostic methods such as enzyme assay
during the study period (some methods were introduced as
late as the 1990s) may explain the lower prevalence rates.
Different frequencies of the various forms of
mucopolysaccharidosis were observed. In the Polish popula-
tion, MPS III (all types) was the most frequently diagnosed
(0.86 per 100,000 live births), followed by MPS II (0.46) and
MPS I (0.22). In almost all published populations, Sanfilippo
syndrome (MPS III) represents the most prevalent
mucopolysaccharidosis. The highest prevalence was found
by van de Kamp in the Netherlands (van de Kamp 1979),
but it was not confirmed by a later study by Poorthuis et al.
(1999), which found a crude rate of 1.89 MPS II cases in
100,000 live births. An unusually high prevalence rate ofMPS
II has been detected in the Ashkenazi Jewish population
(Diamond 1994), while the highest prevalence of MPS I was
found by Nelson in Northern Ireland (1.6 in 100,000 live
births (Nelson 1997). Mucopolysaccharidosis types VI and
VII belong to the less frequent mucopolysaccharidoses in
most populations except for Brazil (Coelho et al. 1997). The
MPS VI incidence values for Poland were the lowest of all the
studies previously published so far. Interestingly, in our pre-
vious study, we found high incidence rates for MPS VI in
countries neighboring with Poland (Jurecka et al. 2014). In
fact, they were the highest in Europe among those reported so
far. The results for Poland showed the lowest incidence rate
published, except for the data of Nelson et al. (2003). The
observed high p.R152W carrier frequency (0.6 %) in the
Lithuanian population indicates a possible founder effect in
this region (Jurecka et al. 2012). The high prevalence of this
mutation (42–43%) observed in the whole series, as well as in
the Slavic origin of the majority of patients homozygous for
this mutation, may suggest that p.R152W is of Slavic and not
Lithuanian origin. Poland, Belarus, and Baltic States
(Lithuania, Latvia, and Estonia) are located next to each other
and form a belt south-east of the Baltic Sea. Historically, in the
17th century, this area consisted of one administrative unit.
The Polish–Lithuanian Commonwealth was a dualistic state
of Poland and Lithuania ruled by a common monarch. It was
the largest and one of the most populous countries of 16th-
and 17th-century Europe, with some 400,000 square miles
(1,000,000 km) of territory (Fig. 2). At the end of World War
II, Poland’s territory decreased from about 380,000 km2 be-
fore the war to about 312,000 km2 at present, and its borders
were shifted markedly. As a result, Poland lost 50 % of its pre-
war territory in the east and received about 35% of its territory
in the west. The territory in the west, which was returned to
Poland after the war, was settled mainly by Poles expelled
from the lost eastern territories, as well as from other regions
of the country (Encyclopaedia Britannica Online 2009).
Because of this, the population in the western part of Poland
is very heterogenous (Tylki-Szymańska et al. 2001). This is in
contrast to the population in Lithuania and Belarus. As our
analysis showed, 25% of theMPSVI patients in Lithuania are
Fig. 1 Relative rate of
mucopolysaccharidoses in Poland
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of Polish origin/ethnicity. This is likely due to the fact that a
number of Poles were unable to relocate to the newly formed
Poland right after the war and, thus, remained in what is
present-day Lithuania. Moreover, the reported percentage of
patients with Polish origin may be underrepresented, as many
Polish families left behind in eastern land were pressured to
hide their ethnicity. Interestingly, two-fifths of MPS VI pa-
tients identified in Poland have their family roots from the area
of Vilnius, Lithuania. Unfortunately, the data from Ukraine
were not available for our study. The precise estimation of
incidence in case of orphan diseases like MPS VI can be
difficult, as patients with attenuated phenotype may stay
symptom-free and undiagnosed for a long time. It is worth
mentioning that the p.R152W mutation has been associated
with an attenuatedMPS VI phenotype, which is often difficult
to recognize and may be easily overlooked (Jurecka et al.
2011, 2012). This may additionally lead to an underestimation
of the frequency of this type in this region. Interestingly, in
2013, two more MPS VI patients were diagnosed in Poland,
one homozygous and one heterozygous for the p.R152W
mutation. Similarly to the previous cases, the families of both
patients originate from Vilnius/northern Ukraine.
In summary, individually, mucopolysaccharidoses are rare
genetic diseases. However, as a group, they represent an
important health problem in Poland. The prevalence data
should be of interest to clinical geneticists, health care author-
ities, patients and their families, patient societies, and labora-
tories involved in the diagnosis of mucopolysaccharidoses. In
addition, it provides useful information for decision-makers
when it comes to estimating the social and genetic burden of
these diseases to society or to considering the implementation
of newborn screening programs for mucopolysaccharidoses.
Prevalence rates studies are a prerequisite to health economic
Table 2 Prevalence and incidence rates of MPS VI
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geographical distribution of MPS
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The black triangles refer to
patients homozygous for
p.R152W mutation; the gray
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patients heterozygous for
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calculations arising from the introduction of expensive thera-
pies like ERT.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
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